HIPRA
Avda. la Selva. 135, 17170 Amer (Girona), Spain
Phone.: (34) 972 43 06 60 · hipra@hipra.com · www.hipra.com

The World Health Organization grants prequalification to HIPRA's COVID-19 vaccine adapted to the XFG.1.1 variant

This WHO prequalification coincides with the inclusion of the vaccine in the vaccine portfolio of the Pan American Health Organization's (PAHO) Regional Revolving Fund

The initial inclusion of the vaccine in PAHO's COVID-19 vaccine portfolio reinforces the company's commitment to global health and expands the range of available vaccination options

Girona, 24 November, 2026 – HIPRA takes a step forward in its international expansion with BIMERVAX®[1], its COVID-19 vaccine. The World Health Organization (WHO) has granted **prequalification to the European-developed, adjuvanted recombinant protein vaccine in its formulation adapted to the XFG.1.1 variant**, further strengthening the international recognition of the biotechnology pharmaceutical company's ability to develop updated vaccines in response to the evolution of the virus.

Following the vaccine's initial prequalification, the company has continued to update its prequalification in line with the COVID-19 vaccine composition recommended by the World Health Organization (WHO).

This milestone builds on the recent regulatory achievements of the **vaccine adapted to the XFG.1.1** variant, which received a **positive opinion** from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), followed by **marketing authorisation** from the European Commission and authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA)[2]. The vaccine has also been included in the UK National Health Service's (NHS) 2026/27 autumn vaccination programme.

A second international milestone: BIMERVAX® joins PAHO's Revolving Fund

In parallel, the Pan American Health Organization's (PAHO) Revolving Fund has included **HIPRA's COVID-19 vaccine in its vaccine portfolio**[3], expanding the options available for COVID-19 immunisation strategies across the Region of the Americas. In HIPRA's case, this is achieved through a recombinant protein-based vaccine, a technology platform that has been widely used in human vaccines for many years.

This technology contributes to **diversifying countries' vaccination strategies and expanding the options available to address public health needs**. The inclusion of the vaccine in PAHO's portfolio brings together HIPRA's scientific and manufacturing capabilities with the international organisation's regional expertise and leadership in aiming for **equitable access to vaccines and health technologies**.

"COVID-19 continues to pose a challenge for healthcare systems and the general population. Receiving prequalification for our COVID-19 vaccine and making progress in accessing the market in the Region of the Americas reflects our commitment to actively contributing to the protection of global public health through

innovative, accessible solutions tailored to the needs of each region," highlights **Eduard Arce, Global Vaccines Director Human Health at HIPRA.**

With these achievements, HIPRA reaffirms its ability to develop, adapt, manufacture and supply innovative vaccines from Europe, while continuing to work with healthcare institutions and international organisations to **expand access to vaccine solutions based on science, innovation and public-private collaboration**.

About HIPRA

HIPRA is a biotechnological pharmaceutical company focused on prevention in animal and human health (One Health), with a wide range of highly innovative vaccines and an advanced diagnostic service. With its claim **"Building immunity for a healthier world"**, HIPRA reaffirms its commitment to contributing solutions that improve global health. The company has a strong international presence with **40 subsidiaries, 3 R&D centers and 6 production facilities** strategically located in Europe (Spain) and the Americas (Brazil). In addition, its extensive international distribution network keeps commercial channels open in nearly 100 additional countries, thus covering all five continents.

Research and development are at the core of its expertise. HIPRA invests **around the 15% of its annual revenue to R&D activities** and infrastructure, focused on the creation and application of the latest scientific advances for the development of innovative vaccines of the highest quality.

HIPRA has a portfolio of vaccines based on different technological platforms, with R&D teams working with a broad range of technologies and biological modalities.

To add further value to its expertise in vaccination, the company also develops medical devices and traceability services for animal health.

Press contacts
Marc Marqués – press@hipra.com – 972 43 06 60
Irene Calle – icalle@harmon.es – P. 609 873 052
José María Nieto – jnieto@harmon.es – P. 689 186 062
Sara Mancebo – smancebo@harmon.es – P. 628 388 791

References

1. European Medicines Agency (EMA). Bimervax: EPAR – Product Information [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/bimervax-epar-product-information_en.pdf
2. Gov.uk [Internet]. Products. Available from: https://products.mhra.gov.uk/search/?search=BIMERVAX&page=1
3. Item PI, Vacunas P, No. USD. Paho.org. FONDO ROTATORIO PARA EL ACCESO A LAS VACUNAS PRECIOS PARA EL AÑO CALENDARIO 2026. Available from: https://www.paho.org/sites/default/files/2026/07/prices-vac-2026-espv2.pdf